Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Patofysiologi og risiko for atrieflimmer oppdaget etter iskemisk hjerneslag (PARADISE)

PAtofysiologien og risikoen for atrieflimmer oppdaget etter iskemisk slag (PARADISE): Prospektiv ikke-intervensjonell kohortstudie

This prospective non-interventional cohort study investigates the pathophysiology of Atrial Fibrillation Detected After Stroke or transient ischemic attack (AFDAS) by comparing the autonomic function and inflammation between patients with AFDAS, patients with atrial fibrillation (AF) diagnosed before the ischemic event or known AF (KAF), and patients with normal sinus rhythm (NSR) after 14 day of cardiac monitoring following the event onset.

Studieoversikt

Status

Fullført

Forhold

Detaljert beskrivelse

This study enrolls patients with acute ischemic stroke at the London Health Sciences Center in London, Ontario, Canada. The heart rhythm of the patients is monitored with a CardioSTAT® Holter device (Icentia) for 14 days after the ischemic event onset. Based on this cardiac monitoring and previous medical history, patients are stratified into three groups: (a) atrial fibrillation detected after stroke or transient ischemic attack (AFDAS), (b) atrial fibrillation diagnosed before the ischemic event or known AF (KAF), and (c) normal sinus rhythm (NSR).

Autonomic function is assessed by the levels of plasma catecholamines, a battery of validated autonomic tests [autonomic reflex screening (ARS)], heart rate variability (HRV) through data obtained by Holter monitoring by standard quantitative analysis methods according to the guidelines of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology and by the analysis of diurnal variation of heart rate. Blood samples are collected for the analysis of inflammatory markers (e.g. CRP, TNF-α, IL-1β, and IL-6), and potential AFDAS predictors such as brain natriuretic peptide (BNP- AFDAS biomarker), endothelin-1 (endothelial dysfunction marker), Lipoprotein(a) [Lp(a)] and thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels, TAFI activity, TAFI single nucleotide polymorphisms (SNPs), apo(a) isoform size and plasma catecholamines levels. Furthermore, specific neuroimaging findings (e.g., specific regions of the insula or its connections) and clinical features (e.g., impaired interoceptive processing, cognitive impairment, etc) are also analyzed. Interoception is assessed using a heartbeat detection task without feedback condition and gait, balance, frailty, and cognitive status in patients are evaluated by the administration of a battery of tests. Stroke recurrence will be assessed by a structured phone interview at 6 and 12 months after the initial stroke.

Studietype

Observasjonsmessig

Registrering (Faktiske)

45

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Ontario
      • London, Ontario, Canada, N6A 5A5
        • University Hospital, London Helath Sciences Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

Ischemic stroke and transient ischemic attack patients presenting at the University Hospital of the London Health Science Center, London, Ontario, Canada.

Beskrivelse

Inclusion Criteria:

  1. MCA territory-transient ischemic attack or -acute ischemic stroke patients seen in the Emergency Department or admitted to University Hospital, London, Ontario, Canada
  2. Age ≥ 18 years old
  3. Patient or Substitute Decision Maker must give written informed consent

Exclusion Criteria:

  1. Patients with autonomic dysfunction such as Parkinson's disease that can be interfering with outcome assessment based on qualified investigator's judgment.
  2. Patients taking tricyclic antidepressant (TCAs)
  3. Patients in whom the acute stroke is primarily hemorrhagic
  4. Patients with both TIA and atrial fibrillation
  5. Patients with both TIA and large vessel disease
  6. Patients with inflammatory diseases

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
AFDAS

patients without history of atrial fibrillation before the qualifying stroke or transient ischemic attack who are diagnosed with atrial fibrillation during the 14 days of monitoring

KAF

atrial fibrillation known before the stroke or transient ischemic attack

NSR

patients without a history of atrial fibrillation who do not develop atrial fibrillation during the 14 days of cardiac monitoring

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Changes and Differences in Autonomic Function
Tidsramme: Within 48 hours of stroke onset and at 12, 30 and 90 days.

Differences in Composite Autonomic Severity Score (CASS) on an 11-point scale between patients with (a) AFDAS, (b) KAF , and (c) NSR

Within 48 hours of stroke onset and at 12, 30 and 90 days.
Changes and Differences in Inflammatory Responses
Tidsramme: Within 48 hours of stroke onset and at 12, 30 and 90 days.

Differences in levels of plasma markers or temporal responses (CRP,TNFα, IL-6, IL-1β, etc) between patients with (a) AFDAS, (b)KAF and (c) NSR.

Within 48 hours of stroke onset and at 12, 30 and 90 days.
Changes and Differences in Heart Rate Variability (HRV)
Tidsramme: At 14 days.

Differences in HRV parameters between patients with (a) AFDAS, and (b) NSR

At 14 days.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Biomarkers
Tidsramme: Within 48 hours of stroke onset, at 12, 30 and 90 days and at 6 months.

Differences in levels of plasma markers (BNP,endothelin-1, Lp(a), and TAFI) or neuroimaging/clinical predictors between patients with (a) AFDAS , (b) KAF and (c) NSR

Within 48 hours of stroke onset, at 12, 30 and 90 days and at 6 months.
Atrial Fibrillation Burden
Tidsramme: At 14 days

Difference in atrial fibrillation burden (sum of atrial fibrillation episodes for a period of time) of AFDAS subjects with mild stroke/TIA compared to AFDAS subjects with moderate/severe stroke.

At 14 days
Gait Impairments
Tidsramme: At 6 months

Differences in gait parameters in patients with a) AFDAS , (b) KAF and (c) NSR.

At 6 months
Frailty
Tidsramme: At 6 months

Differences in frailty in patients with (a) AFDAS , (b) KAF and (c) NSR

At 6 months
Cognitive Impairment
Tidsramme: At 6 months

Differences in cognition in patients with (a) AFDAS , (b) KAF and (c) NSR

At 6 months

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Stroke Recurrence
Tidsramme: At 90, 180, and 360 days

Number of stroke recurrences in patients with (a) AFDAS , (b) KAF and (c) NSR

At 90, 180, and 360 days
Death
Tidsramme: At 90, 180, and 360 days

Number of deaths in (a) AFDAS , (b) KAF and (c) NSR groups

At 90, 180, and 360 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Luciano A Sposato, MD, Lawson Health Research Institute, London Health Sciences Center, Western University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

18. april 2017

Primær fullføring (Faktiske)

29. april 2019

Studiet fullført (Faktiske)

26. mars 2020

Datoer for studieregistrering

Først innsendt

24. august 2017

Først innsendt som oppfylte QC-kriteriene

5. september 2017

Først lagt ut (Faktiske)

7. september 2017

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. september 2026

Sist bekreftet

1. mars 2025

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • R-17-032

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .